RxDoctor Payments Data

Mari Looney

Family · Monroe, NCNPI 1366086027

Payments from drug & device makers

$2,432in general payments, 2019–2025

Across 90 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$880
  • Ironwood Pharmaceuticals, Inc$273
  • Takeda Pharmaceuticals U.S.A., Inc.$240
  • Nestle Healthcare Nutrition Inc.$170
  • QOL Medical, LLC$154
  • Ferring Pharmaceuticals Inc.$114
  • plus $602 from 15 others

What the payments were for

  • Food & beverage$2,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,432 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$79,494
Medicare patients
482
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase39$159,621
LinzessLinaclotide49$39,060
TrulancePlecanatide21$18,953
MovantikNaloxegol Oxalate20$11,764
Mesalamine36$9,121
Pantoprazole Sodium201$3,701
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C21$2,899
Omeprazole123$1,445
Sucralfate33$1,307
Famotidine51$908
Dicyclomine Hcl27$855
Budesonide DrBudesonide11$825
Ondansetron OdtOndansetron24$317
Esomeprazole Magnesium11$306
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$880$198,68188 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$50$21,85242 claims
Redhill Biopharma Inc.Movantik$18$11,76420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.

Other family in Monroe

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →